DNA Biomed Solns
Dna Group (T.R.) Ltd, together with its subsidiaries, engages in the development, manufacturing, and marketing of patented ultrasound systems in Israel, North America, East Asia, and internationally. It provides systems for diagnosing bone strength and density, as well as for monitoring calcium leakage (osteoporosis) in adults and children. The company offers its products for use by skilled physi… Read more
DNA Biomed Solns (DNA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2023: -0.003x
Based on the latest financial reports, DNA Biomed Solns (DNA) has a cash flow conversion efficiency ratio of -0.003x as of June 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-265.00K) by net assets (ILA82.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DNA Biomed Solns - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how DNA Biomed Solns's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
DNA Biomed Solns Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DNA Biomed Solns ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Insplorion AB
ST:INSP
|
-0.139x |
|
BCO LATINOAM -E (D8Q.SG)
STU:D8Q
|
0.364x |
|
BEKAERT (BK8N.SG)
STU:BK8N
|
-0.004x |
|
IBIDEN
MU:IBI
|
0.215x |
|
Vaziva Sa
PA:ALVAZ
|
N/A |
|
NANOSPHERE
F:3NS
|
-0.003x |
|
BUZZI UNICEM - Dusseldorf Stock Exchang
DU:UCM
|
N/A |
|
BRUKER
BE:BKD
|
0.021x |
Annual Cash Flow Conversion Efficiency for DNA Biomed Solns (2013–2024)
The table below shows the annual cash flow conversion efficiency of DNA Biomed Solns from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA101.47 Million | ILA1.61 Million | 0.016x | +285.32% |
| 2023-12-31 | ILA79.19 Million | ILA-678.00K | -0.009x | -93.75% |
| 2022-12-31 | ILA80.11 Million | ILA-354.00K | -0.004x | +89.70% |
| 2021-12-31 | ILA54.33 Million | ILA-2.33 Million | -0.043x | +44.17% |
| 2020-12-31 | ILA7.95 Million | ILA-611.00K | -0.077x | -57.74% |
| 2019-12-31 | ILA28.18 Million | ILA-1.37 Million | -0.049x | -90.35% |
| 2018-12-31 | ILA64.90 Million | ILA-1.66 Million | -0.026x | +7.16% |
| 2017-12-31 | ILA69.11 Million | ILA-1.91 Million | -0.028x | -116.08% |
| 2016-12-31 | ILA-83.41 Million | ILA-14.30 Million | 0.171x | -90.81% |
| 2015-12-31 | ILA-8.35 Million | ILA-15.57 Million | 1.865x | +41.84% |
| 2014-12-31 | ILA-8.36 Million | ILA-10.99 Million | 1.315x | +391.99% |
| 2013-12-31 | ILA11.49 Million | ILA-5.17 Million | -0.450x | -- |